Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Recbio Technology CoHKSE:02179 24 Median PS Value is HK$0.00 as of Aug. 25, 2026. GuruFocus rates HKSE:02179 with a GF Score™ of 24/100. The stock has 6 warning signs investors should review. Among 282 Biotechnology companies, Jiangsu Recbio Technology Co ranks worse than 354609.57% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Jiangsu Recbio Technology Co's Median PS Value or its related term are showing as below:
HKSE:02179's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.63 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Jiangsu Recbio Technology Co (HKSE:02179) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Jiangsu Recbio Technology Co's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
5.00
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Recbio Technology Co Median PS Value Related Terms
Jiangsu Recbio Technology Co Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Recbio Technology Co Median PS Value Chart
HKSE:02179 vs VRTX, REGN, RVMD: Median PS Value Comparison
For the Biotechnology subindustry, Jiangsu Recbio Technology Co's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Recbio Technology Co Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jiangsu Recbio Technology Co's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Jiangsu Recbio Technology Co's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jiangsu Recbio Technology Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Recbio Technology Co (HKSE:02179) has a Median PS Value of HK$0.00 as of Aug. 25, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Jiangsu Recbio Technology Co and its competitors. According to the industry distribution chart, Jiangsu Recbio Technology Co ranks #999999 out of 282 companies in the Biotechnology industry.
Is Jiangsu Recbio Technology Co's Median PS Value too high?
Jiangsu Recbio Technology Co's current Median PS Value is HK$0.00. Based on the distribution chart, Jiangsu Recbio Technology Co ranks #999999 out of 282 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jiangsu Recbio Technology Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Recbio Technology Co's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jiangsu Recbio Technology Co ranks #999999 out of 282 companies for Median PS Value. This places Jiangsu Recbio Technology Co in the lower half of its industry. The industry median Median PS Value is 0.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 282 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Jiangsu Recbio Technology Co and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Recbio Technology Co's current Median PS Value is HK$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Recbio Technology Co stock overvalued right now?
Jiangsu Recbio Technology Co (HKSE:02179) has a current Median PS Value of HK$0.00. The current Median PS Value is HK$0.00. Jiangsu Recbio Technology Co's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Jiangsu Recbio Technology Co (HKSE:02179), the current Median PS Value is HK$0.00 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangsu Recbio Technology Co Ltd is a vaccine company focused on the research, development, and commercialization of vaccines, with a high-value vaccine portfolio driven by in-house technologies. It has built three vaccine technology platforms: novel adjuvants, protein engineering, and immune evaluation. The company's portfolio currently consists of various vaccines, covering diseases such as cervical cancer, herpes zoster, and respiratory syncytial virus. It has two core strategic products, namely REC610, a novel adjuvanted recombinant shingles vaccine, which is currently in the stage of marketing application in China, and REC603, a recombinant HPV 9-valent vaccine under phase three clinical trial.
24GF Score
Get the complete analysis for HKSE:02179
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02179 has been successfully added to your 
